Quentin M Anstee Selected Research

Type 2 Diabetes Mellitus (MODY)

1/2024	Prognostic utility of Fibrosis-4 Index for risk of subsequent liver and cardiovascular events, and all-cause mortality in individuals with obesity and/or type 2 diabetes: a longitudinal cohort study.
1/2023	Expert Panel Consensus on Clinical Assertion Statements Describing Noninvasive Tools for Diagnosing Nonalcoholic Steatohepatitis.
1/2023	A proteo-transcriptomic map of non-alcoholic fatty liver disease signatures.
1/2023	The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326.
12/2020	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis.
1/2013	Mutations in Mll2, an H3K4 methyltransferase, result in insulin resistance and impaired glucose tolerance in mice.
2/2012	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: evidence from case-control and intra-familial allele association studies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Quentin M Anstee Research Topics

Disease

83	Non-alcoholic Fatty Liver Disease 04/2024 - 07/2011
64	Fibrosis (Cirrhosis) 04/2024 - 02/2009
24	Liver Cirrhosis (Hepatic Cirrhosis) 04/2024 - 09/2012
19	Alcoholic Fatty Liver 12/2023 - 09/2010
17	Fatty Liver 01/2024 - 09/2010
15	Liver Diseases (Liver Disease) 04/2024 - 11/2012
14	Inflammation (Inflammations) 01/2023 - 02/2009
7	Type 2 Diabetes Mellitus (MODY) 01/2024 - 02/2012
7	Hepatocellular Carcinoma (Hepatoma) 08/2023 - 08/2017
5	Disease Progression 12/2023 - 01/2021
5	Weight Loss (Weight Reduction) 10/2023 - 10/2013
5	Insulin Resistance 01/2018 - 01/2013
4	Obesity 01/2024 - 01/2013
3	Pruritus (Itching) 01/2022 - 12/2019
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 04/2013
2	Diarrhea 01/2024 - 10/2021
2	Nausea 01/2024 - 10/2021
2	Weight Gain 10/2021 - 01/2016
2	Alcoholic Liver Diseases (Alcoholic Liver Disease) 01/2017 - 06/2016
2	Chronic Hepatitis C 09/2011 - 02/2009
2	Protein C Deficiency 09/2011 - 02/2009
1	End Stage Liver Disease 04/2024
1	Hepatic Encephalopathy 08/2023
1	Hemorrhage 08/2023
1	Ascites 08/2023
1	Neoplasms (Cancer) 12/2022
1	Chronic Disease (Chronic Diseases) 01/2022

Drug/Important Bio-Agent (IBA)

30	Biomarkers (Surrogate Marker)IBA 12/2023 - 10/2013
12	LipidsIBA 05/2022 - 01/2013
8	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2024 - 06/2013
8	Triglycerides (Triacylglycerol)IBA 01/2023 - 06/2014
8	EnzymesIBA 10/2022 - 01/2013
8	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2013
7	Proteins (Proteins, Gene)FDA Link 04/2024 - 06/2016
7	nasIBA 12/2023 - 05/2012
6	obeticholic acidIBA 11/2023 - 05/2015
5	RNA (Ribonucleic Acid)IBA 04/2024 - 01/2018
5	CollagenIBA 10/2023 - 01/2015
5	selonsertibIBA 01/2023 - 11/2019
5	Alanine Transaminase (SGPT)IBA 01/2022 - 06/2013
4	cenicrivirocIBA 10/2023 - 01/2020
4	Complement C3 (C3 Complement)IBA 10/2023 - 09/2019
3	Immunoglobulin A (IgA)IBA 01/2023 - 05/2014
3	Phospholipases (Phospholipase)IBA 10/2022 - 06/2016
3	Insulin (Novolin)FDA Link 01/2021 - 01/2013
3	CytokinesIBA 01/2018 - 01/2017
2	resmetiromIBA 01/2024 - 01/2024
2	tropifexorIBA 10/2023 - 01/2020
2	AntigensIBA 01/2023 - 11/2017
2	Immunoglobulins (Immunoglobulin)IBA 01/2023 - 05/2014
2	Choline (Choline Chloride)IBA 01/2023 - 09/2010
2	Syntex adjuvant formulationIBA 02/2022 - 10/2021
2	MicroRNAs (MicroRNA)IBA 02/2022 - 01/2022
2	Oxidoreductases (Dehydrogenase)IBA 01/2022 - 02/2015
2	Peptides (Polypeptides)IBA 10/2021 - 01/2020
2	HDL LipoproteinsIBA 01/2020 - 01/2019
2	Thrombin FDA Link 05/2018 - 02/2009
2	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 01/2015
2	CreatinineIBA 01/2016 - 03/2015
2	Blood Glucose (Blood Sugar)IBA 01/2016 - 03/2015
2	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2016 - 09/2012
2	Histones (Histone)IBA 01/2013 - 09/2012
2	ChromatinIBA 01/2013 - 09/2012
2	Fatty Acids (Saturated Fatty Acids)IBA 02/2012 - 11/2010
2	Factor VIII (Coagulation Factor VIII)IBA 09/2011 - 02/2009
2	Fibrinogen (Factor I)FDA Link 09/2011 - 02/2009
2	FibrinIBA 09/2011 - 02/2009
2	factor V LeidenIBA 09/2011 - 02/2009
1	Messenger RNA (mRNA)IBA 04/2024
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 04/2024
1	Thyroid Hormone Receptors beta (TR beta)IBA 01/2024
1	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 01/2024
1	GoldIBA 01/2024
1	semaglutideIBA 12/2023
1	Complement C4 (Complement Component 4)IBA 10/2023
1	cyclo(Arg-Pro) (CI 4)IBA 08/2023
1	Chemokine ReceptorsIBA 04/2023
1	gamma-Glutamyltransferase (gamma-Glutamyl Transpeptidase)IBA 01/2023
1	Immunoglobulin E (IgE)IBA 01/2023
1	IgA receptor (protein B)IBA 01/2023
1	SolutionsIBA 01/2023
1	Transaminases (Aminotransferases)IBA 01/2023
1	TransferasesIBA 01/2023
1	CholesterolIBA 01/2023
1	Sorafenib (BAY 43-9006)FDA Link 12/2022
1	very low density lipoprotein triglycerideIBA 10/2022
1	GlycosphingolipidsIBA 09/2022
1	GlycosaminoglycansIBA 09/2022
1	VitaminsIBA 09/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2022
1	amidoximeIBA 01/2022
1	Scavenger Receptors (Scavenger Receptor)IBA 01/2022

Therapy/Procedure

19	Therapeutics 12/2023 - 11/2012
6	Liver Transplantation 04/2024 - 07/2011
6	Drug Therapy (Chemotherapy) 12/2023 - 05/2015
2	Caloric Restriction 10/2023 - 01/2020
2	Diet Therapy (Therapy, Diet) 01/2022 - 05/2015
2	Mediterranean Diet 01/2022 - 01/2019
2	Transplantation 10/2019 - 10/2019
1	Aftercare (After-Treatment) 01/2022